Vendor Intelligence Report: Penguin Peptides

Executive summary

Across 5 Finnrick lab tests, Penguin Peptides records 4 pass / 1 fail — an 80% overall pass rate. That headline is entirely Tirzepatide. The signal is useful but narrow: better than an untested storefront, weaker than vendors with longer clean Tirzepatide runs, and materially sensitive to stricter grading.

Penguin Peptides is not best read as a disposable no-record shop. The report confirms a Wyoming LLC, EIN, active storefront, public Janoshik entries, and visible social promotion. The same chronology shows a very young operation: domain history, formation records, community visibility, and ranking-page appearances all cluster inside roughly one operating year.

The accountability trail is the sharper concern. Corporate records point to a Sheridan, Wyoming registered-agent address used at scale, while the site names no founders, managers, quality lead, or responsible officer. A California phone number adds operating-location ambiguity, and privacy-protected domain data leaves beneficial ownership unresolved.

Quality documentation also splits positive from practical. Public lab artifacts exist, including Janoshik entries and a lab-results page, but the report tracks how gallery-style COAs can fall short of lot-level verification. It also maps a small discount-code ecosystem where personal referral paths and Reddit/X code promotion appear without clear disclosure.

Inside the full report:

• Finnrick Tirzepatide pass/fail record with methodology-divergence and rating-trajectory exhibits
• Corporate-record timeline using domain history, Wyoming LLC materials, EIN/footer captures, and Wayback artifacts
• Registered-agent address analysis for 1309 Coffeen Avenue STE 1200 and operating-location caveats
• COA usability review with public Janoshik entries for BPC-157 + TB-500, GLP-1 T, and HGH 191AA
• Affiliate and promotion scan covering /ref/105, Brew20, STARSHIP25, coupon aggregators, and channel ambiguity
• Buyer guidance separating Penguin’s Tirzepatide evidence from the ungraded rest of the catalog

Risk assessment

• Ownership and operating-location opacity — high: Wyoming LLC uses 1309 Coffeen Avenue STE 1200, a high-volume registered-agent address; no named personnel were found and the California phone number leaves actual operations unresolved.
• Product-quality consistency risk — Tirzepatide — medium: Finnrick data covers Tirzepatide only and shows 5 tests, 4 pass / 1 fail, with a 79.36% rating.
• COA and batch-verification gap — medium: Janoshik entries and a lab-results page exist, but user reports and site review indicate COAs are not consistently delivered as batch-specific, pre-purchase verification documents.
• Unverified sourcing-claims risk — medium: Claims about certified North American manufacturers and WHO/GMP or ISO-style standards were not supported by named suppliers or certificates in the public record.
• Affiliate and brand-channel confusion risk — medium: Personal referral paths and codes appeared without clear disclosure, coupon sites amplify codes, and the research materials surfaced conflicting X-handle signals without an authoritative channel list.
• Buyer-remedy risk — medium: Refund terms are “All Sales Final,” with refunds or replacements at Penguin Peptides’ sole discretion.